Prescient Therapeutics starts Phase 1b clinical trial of its unique inhibitor PTX-100

On 11 July 2019, Prescient Therapeutics Limited (ASX: PTX) announced the commencement of a Phase 1b trial of its second targeted anti-cancer drug PTX-100...

Prescient Therapeutics’ drug candidates addressing the mutations causing cancer

Clinical-Stage oncology company, Prescient Therapeutics Limited (ASX: PTX) bases the foundation of its business model on the ground-breaking technology that addresses the mutations causing...

All that investors need to know about clinical stage oncology company, Prescient Therapeutics

Prescient Therapeutics Limited (ASX: PTX), based in South Melbourne, Australia, is an oncology company (clinical-stage) that develops novel drugs and targeted therapies to treat...

Prescient Therapeutics Announces The Receipts of R&D Tax Rebate

On 15 January 2019, Prescient Therapeutics Limited (ASX: PTX) announced that the company had received Tax Incentive rebate on research and development for the...

Latest News

Editorial

Three Stocks from the Health Care Sector: ATX, SOM & M7T

In this article, we would discuss three healthcare stocks from ASX. On 23 July 2019, these companies have released significant updates pertaining to their...

Has China Internet Bubble Burst? Impact on Aussie Fund Managers   

The first Internet bubble, called Dot-Com Boom, emerged between the late 1990s and early 2000s. During the bubble, Internet-based companies in the United States...
Facebook Comments